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The many dimensions of narcotics control in 
Finland
Sami Paaskoski
Senior Pharmaceutical Inspector
National Agency for Medicines
Editorial
What do the analgetic morphine, the sedative di-
azepam, and acetone, used as an industrial solvent,
have in common? What is the common denomina-
tor linking pharmaceutical companies, pharmaceu-
tical wholesalers and pharmacies, the chemical in-
dustry, and the municipal waterworks? The answer:
Although these substances and groups are very dif-
ferent, they all fall under NAM’s scope of responsi-
bility in the field of narcotics control.
The new Act on Narcotics (373/2008) will enter
into force on 1st September 2008. Narcotics con-
trol will be improved thanks to the new procedures
that are to be introduced with regard to permits
and notices, with increased co-operation between
authorities. The responsibilities and duties of those
parties involved in dealing with narcotics will be
emphasised more precisely in the applicable legal
provisions.
International narcotics control is based on the
United Nations Conventions; the principle govern-
ing these is to ensure the availability of controlled
substances for medicinal use and scientific research,
while preventing abuse of the substances. The Sin-
gle Conventions on Narcotic Drugs from 1961 and
Psychotropic Substances from 1971 are still the key
instruments of narcotics legislation. The new Act
will not affect the principles of Finland’s national
narcotics policy.
The term ‘narcotic substance’ gives rise to pow-
erful associations which frequently cause confusion
in patients. For its definition of a narcotic sub-
stance, national legislation continues to rely on the
substances listed in the international conventions.
Opioids, for example, and the majority of medi-
cines whose main effect is a CNS effect, fall within
the scope of the conventions and are therefore
legally narcotic substances. Justified medicinal use
of the substances in the treatment of patients
should be clearly distinguished from abuse, which
leads to dependency.
Control of the precursors used in the manufac-
ture of narcotic substances is also the responsibility
of the National Agency for Medicines. The precur-
sors regulated include some substances which are
also used as medicines, and certain commonly-
used, high-volume industrial chemicals, which are
needed for the manufacture of narcotics. Water pu-
rification processes may involve the use of potassi-
um permanganate, the use of which, if it exceeds a
certain threshold value, requires user registration
with NAM. The same chemical is also used in the
manufacture of cocaine. Narcotics and narcotics
control thus have some unexpected dimensions.
Areas of concern in the enactment of the law in-
cluded falsification of prescriptions for medicines
which are classified as narcotics, and the risk of
these medicines becoming the object of abuse. Spe-
cial issues raised included new substances which
are imported and used for purposes of intoxication,
but which are not actually narcotics. What quick
action can be taken here? Classifying them nation-
ally as narcotics is not a possibility, whereas having
the substance regulated under international control
is a long process. There are still a number of issues
awaiting to be resolved.
The long process of drafting legislation has
reached its end, and the process of practical imple-
mentation of the new regulation procedures has
started. This provides an opportunity to re-examine
the present procedures. New duties of supervision
at NAM have furthermore required consolidation
of resources. NAM is a key authority in the regula-
tion of the legalised use of narcotic substances and
their precursors.
Problems of drug treatment in the elderly 
in accident and emergency departments
As the population ages, increase
in the number of diseases associ-
ated with the usual ageing
process is an obvious reason for
the common sight of elderly pa-
tients (over 75–80 years of age)
in accident and emergency de-
partments. The elderly admitted
to these departments typically
have multiple diseases and use
several drugs. This paper dis-
cusses drug treatment of the el-
derly as a cause of hospitalisa-
tion, and it also deals with how
drug treatment should be taken
into account when planning
treatment.
Drug treatment and reasons
for admission to accident and
emergency departments
Drug treatment can lead to hos-
pitalisation in several ways, and
this, along with associated ad-
verse drug reactions has often
been considered a significant
cause of hospitalisation of the el-
derly. The combination of dis-
eases and drug treatment makes
assessment difficult, however.
With regard to the elderly in par-
ticular, it is often difficult to un-
ravel whether the cause is med-
ication or a disease. Confound-
ing by indication should be taken
into account when causal rela-
tionships are examined. Indica-
tive figures have been received
from studies in recent years. An
extensive British study (covering
nearly 19,000 emergency atten-
dances), about 6.5% of the caus-
es of hospitalisation were the re-
sult of adverse drug reactions (1).
The average age of these patients
was 76 years. This correlated
well with a study carried out in
1996, consisting of a review of
elderly Finnish patients: adverse
drug reactions were the cause of
hospitalisation in 6% of them
(2). According to an American
study, every year 4% of elderly
drug users experience a severe
adverse drug reaction (3). Of all
adverse drug reactions, less than
1% led to death (3). The out-
come was lethal in 2% of the pa-
tients who had adverse reactions
requiring hospitalisation (1). 
A recent Swedish review con-
sisted of a one-month analysis of
the reasons, associated with drug
treatment for admission to a uni-
versity hospital internal medicine
emergency department (4). The
total number of patients with an
average age of 68 years was
1,176, 39% of whom were hos-
pitalised (n=457). Of the pa-
tients, 135 (12% of the total
number, 30% of those hospi-
talised) were considered to have
problems with drug treatment
which either directly or indirectly
were the cause of them requiring
hospitalisation. Of these patients,
73% were assessed as having ex-
perienced a drug-induced symp-
tom, the drug treatment was in-
adequate or otherwise unsuccess-
ful in 30%, toxicity was the
cause for hospitalisation in 5%,
and drug abuse in 11% of the
patients, and 48% of them were
thought to have experienced a
clinically significant interaction.
The figures of adverse drug reac-
tions in the Swedish study are
quite high, but the study was car-
ried out in a university hospital
(Karolinska Hospital, Stockholm)
where the patients have severe
multiple diseases (cardiology,
haematology and cancer patients)
and are consequently on multiple
drugs (average of 9 drugs); a
third of the patients suffered
from renal failure.
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Table 1. Categorisation of adverse reactions associated with drug treatment
Intentional overdose
Involuntary adverse reactions
• allergic reactions (transmitted via the immune system) 
• actual adverse reactions (pharmacological or idiosyncratic reactions 
associated with usual doses)
• involuntary overdose
• secondary reactions (e.g. a fall associated with hypotension)
• interaction with another drug or disease
Adverse reactions associated
with drug treatment can be cate-
gorised as shown in Table 1.
All types of adverse reactions,
including intentional overdose,
may occur in the elderly, and par-
ticularly in the case of an elderly
person with memory loss, an in-
voluntary overdose should also
be considered. An adverse reac-
tion associated with the drug or
its secondary reaction is often a
contemplated risk which is taken
when treatment for a disease is
necessary. Well-known examples
of these include the risk of haem-
orrhage with the use of warfarin
and the side-effects associated
with antibiotic and corticosteroid
therapy. In general, the majority
of the significant adverse drug re-
actions experienced by the elderly
are associated with well-known
and widely used drugs such as
anticoagulants, anti-inflammatory
analgesics and antidiabetic
agents, whereas surprisingly few
are associated with drugs that
can be called inappropriate (5)
(Table 2).
The interrelation between the
medication of 450 elderly pa-
tients and their hospitalisation
was analysed in a Finnish study
published in 1996 (2). The most
significant causes were extrapyra-
midal symptoms caused by an-
tipsychotics, haemorrhage caused
by warfarin and anti-inflammato-
ry analgesics, and diarrhoea
caused by antibiotics. 
In a British study, typical se-
vere adverse reactions included
intestinal haemorrhage caused by
acetylsalicylic acid, other anti-in-
flammatory analgesics and war-
farin; hypotension or renal failure
caused by diuretics or ACE in-
hibitors; antidepressant induced
confusion, hypotension, constipa-
tion, intestinal haemorrhage or
hyponatraemia; and beta-blocker
induced bradycardia, hypotension
and chronic obstructive pul-
monary disease (1). 
In an American study (3, 5),
cardiovascular drugs, antibiotics,
diuretics and anti-inflammatory
analgesics were also considered to
be the most common causes of
adverse reactions.
An important message to
come out of the studies has also
been the fact that a very high
proportion of the adverse drug
reactions suffered by the elderly
are preventable. It is estimated
that as many as 40% to 70% of
the reactions are avoidable in ide-
al circumstances and by correct
adjustment of the drug dose, for
example (1–4). On the other
hand, even though antibiotics
generally cause adverse reactions,
only a small proportion of them
could be prevented (3). In severe
adverse reactions the possibility
of prevention is generally estimat-
ed to be higher than in milder re-
actions. This promotes improved
identification of adverse drug re-
actions and their causes.
Multi-drug medication may
cause interactions. A British study
showed the proportion of interac-
tions to be 16.6% of adverse
drug reactions (1), but in patients
with multiple diseases and on
multiple drug therapies at a
Swedish university hospital, it
was estimated that every second
patient experienced a clinically
significant interaction (4). Never-
theless, it is generally estimated
that interactions are theoretically
are very common, but only a
small proportion are clinically
significant (6). A Canadian study
comprising patients aged over 65
with osteoarthritis, showed the
ratio of interactions of clinically
significant drug interactions and
all possible interactions to be 1:6
(7), i.e. about 16% of interac-
tions were significant. The impor-
tant drugs to bear in mind in re-
spect of interactions include the
well-known warfarin, acetylsali-
cylic acid and diuretics. Neverthe-
less, a clinician treating elderly
patients should be aware of these
and should avoid possibly haz-
ardous interactions. Nowadays
significant interactions can be
identified, even at the bedside,
with the help of the SFINX data-
base, for example (www.terveys-
portti.fi). The important drugs to
bear in mind are listed in Table 3.
Typical and unexpected inter-
actions of drugs metabolised via
the liver, and which should be ac-
counted for in the treatment of
the elderly, are considered in a re-
cent Finnish review (8). Several
drugs causing significant interac-
tions can in fact be considered in-
appropriate for the elderly from
the start, because there are safer
alternatives.
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Table 2. Key inducers of severe drug
reactions (not in order of importance)
• Warfarin
• Acetylsalicylic acid 
• Anti-inflammatory analgesics
• Diuretics
• ACE inhibitors
• Beta-blockers
• Insulin and oral antidiabetic agents
• Antimicrobials
• Drugs with a narrow therapeutic range 
(e.g. lithium) 
Table 3. Possibility of an interaction to
be borne in mind when elderly people are
on any of the following drug therapies
• Warfarin
• Acetylsalicylic acid
• Diuretics
• Amitriptyline
• Doxepin
• Fluoxetine
• Levomepromazine
• Perphenazine
• Phenytoin
• Carbamazepine
• Alprazolam
• Diazepam
• Midazolam
• Triazolam
• Diltiazem
• Verapamil
• Omeprazole
• Antifungals
Problems associated with
treatment and specific symp-
toms of the elderly while 
receiving drug treatment
Even though drug treatment of
the elderly in emergency depart-
ments often takes place following
principles similar to those ap-
plied in younger patients, elderly
patients may have special charac-
teristics which should be consid-
ered when planning their drug
treatment (Table 4).
Renal function is often im-
paired – exposing the patient to
e.g. electrolyte disturbances and
adverse drug reactions – and the
creatinine level alone does not re-
veal the whole truth about the
condition of the patient’s kid-
neys. The elderly patient may
suffer from orthostatic hypoten-
sion, and measurement of blood
pressure as well in the upright
position is important when man-
agement with antihypertensives
and antihypotensives is planned.
Delirium, tendency to fall over,
cognitive impairment (dementia)
and frailty syndrome, especially
common in those over 80, also
have an effect on other diseases
and associated treatment. It is
recommended that these special
problems be identified, but an el-
derly person’s dementia must not
lead to unnecessarily negative at-
titudes, for example. Infections
and cardiac problems in demen-
tia patients must also be treated.
Frailty syndrome, dementia and
delirium are associated with re-
duced capacity of the body’s re-
serves, in which case the drug re-
sponse may be unexpectedly
strong. Anticholinergics in partic-
ular should be avoided and,
should their use be necessary, the
response should be carefully
monitored, especially in patients
with dementia and delirium (9).
Since the elderly are usually on
several drug therapies, a thor-
ough review of an updated list of
drugs (not forgetting any herbal
and natural remedies which the
patient does not necessarily men-
tion) is important both in the as-
sessment of possible hospitalisa-
tion and planning of future man-
agement. Problems often occur
with the availability of an updat-
ed list of drugs, however. Devel-
opment including the common
use of IT systems is required, as
well as sharing of responsibility
with regard to who is registering
what and into where. Good read-
ability of lists of drugs is also
very important.
Problems with medication 
following attendance at the
emergency department
Medication introduced in emer-
gency care also influences the pa-
tient’s future condition, as dis-
covered among emergency unit
patients over 65 years of age in
an American hospital for veter-
ans (10). Of the patients, 45%
(942) had received one or more
new drugs during an attendance.
A third of the patients experi-
enced potential problems associ-
ated with the newly introduced
drug: inappropriate medication,
a drug interaction or a drug–dis-
ease interaction. A third of the
veterans were rehospitalised and
the outcome was fatal for 2%
during the follow-up period.
Problems associated with medica-
tion increased these risks by
32%. In an effort to reduce the
number of future emergency at-
tendances, improved monitoring
of drug treatment should be con-
sidered.
Conclusion
An adverse drug reaction may be
a significant reason why an elder-
ly patient is admitted to an emer-
gency department. Adverse drug
reactions may often, however, be
well-known adverse reactions of
a drug which is essential. The
most common ones include war-
farin, acetylsalicylic acid, anti-in-
flammatory analgesics, diuretics,
ACE inhibitors, beta-blockers
and insulin. A disease in an el-
derly patient may, on the other
hand, significantly reduce the
drug response. 
See literature on page 6.
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Table 4. Specific symptoms of elderly patients in emergency departments which may
influence drug therapy
• Delirium – drugs with a CNS effect, anticholinergics
• Cognitive impairment – drugs with CNS effect, anticholinergics
• Frailty syndrome – impairment of the body’s reserves, drug response
• Tendency to fall over - drugs with a CNS effect, antihypertensives
• Impaired renal function – drug response, electrolyte disturbances
• Orthostatic hypotension - antihypertensive medication
While the elderly patient is in
the emergency department, the
following should be considered
• check what medicines and 
herbal remedies were used,
including the part they played 
in the fact that the patient was
hospitalised.
• check whether the patient 
suffers from a frailty syndrome, 
dementia, delirium, renal failure
(not necessarily shown by the
creatinine level) or orthostatic
hypotension, and adjust the
drug treatment accordingly.
Since a significant proportion 
of drug adverse reactions are
preventable, special attention
should be paid to the drug
treatments introduced in the
emergency department including
their efficacy, and to monitoring
their effects.
Management of schizophrenia is
based on a long-term relationship
and an individual management
plan which is regularly reviewed
and which takes into considera-
tion the needs of the patient and
of those nearest to him/her. Key
issues in management include an
antipsychotic medication aimed
at using the smallest effective
dose and minimising adverse re-
actions; various forms of individ-
ual psychosocial treatment, edu-
cation of the whole family about
the disease, and forms of social
rehabilitation. In long-term man-
agement it is important to sup-
port the patients adherence to
their treatment; equally impor-
tant are flexible services in crisis
situations and prevention of new
episodes of illness. (1). 
Used regularly, antipsychotics
alleviate symptoms of the acute
stage and prevent recurrence of
psychosis. Antipsychotics are of-
ten used for a long time over
years and decades, and long-term
tolerability in particular is conse-
quently important. As conven-
tional antipsychotics are not ef-
fective in all patients and their
use is associated with a large
number of neurological adverse
effects, new drugs have been de-
veloped with a broader effect on
psychotic symptoms and a better
level of tolerance. It has neverthe-
less been found in recent years
that antipsychotics can have
metabolic and cardiovascular ef-
fects. Long-term weight increase
is the biggest risk factor for adult
type diabetes, and metabolic syn-
drome associated with being
overweight also includes other
significant cardiovascular risk
factors. Identifying changes in
metabolism and weight linked to
the use of antipsychotics is im-
portant and helps to improve the
benefit/adverse effect ratio. Se-
lecting the correct antipsychotic,
avoiding multiple medications,
giving nutritional advice, measur-
ing weight regularly and partici-
pating in a diet program as neces-
sary can decrease these adverse
effects. Regular monitoring in
line with recent recommendations
can improve the prognosis for
this patient group (2).
Sugar metabolism disorders
Impaired control of diabetes, as
well as new incidences of diabetes
have been described in the use of
anti-psychotics; in particular, if
the patient was overweight at the
outset of treatment or the weight
was increased significantly at the
start of the treatment. Incidences
of diabetes have been described
both with conventional antipsy-
chotics and with second genera-
tion drugs. The prevalence of dia-
betes or impaired tolerance of
sugar in schizophrenic patients is
difficult to assess, but figures in
the range of 2.7%–36.6% have
been suggested. In small trials the
risk of diabetes is estimated to be
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Schizophrenia, the most difficult type of psychosis, is a multiform psychiatric disease affecting about
one percent of the adult population. Schizophrenia has often been considered a chronic disorder, but
prognosis can be improved by early identification of the disease and early introduction of treatment.
Key issues in management include an antipsychotic medication aimed at using the smallest effective
dose and minimising adverse reactions.
about two to four times higher in
comparison with the normal
population. According to a re-
cent extensive study, the develop-
ment of diabetes is more com-
mon in patients on second gener-
ation antipsychotics, especially in
patients under 40 years of age
(3).
Changes in fat metabolism
The exact cause of lipid changes
associated with antipsychotic
therapy is unclear, but lipid
changes may be linked to the
weight gain associated with the
use of these drugs. Accumulating
fat around the middle of the
body increases the presences of
free fatty acids in the liver, accel-
erates liver triglyceride synthesis
and VLDL lipoprotein secretion.
The increased concentration of
free fatty acids may also compete
with the absorption of glucose,
especially in muscle tissues, and
may lead to impaired sugar toler-
ance and type 2 diabetes. Among
the conventional anti-psychotics,
soon after their introduction on
to the market phenothiazines
(e.g. chlorpromazine) were found
to increase the serum cholesterol
and particularly triglyceride con-
centrations; with butyrophe-
nones, such as haloperidol the
corresponding effects were some-
what smaller. Among the second
generation antipsychotics clozap-
ine therapy has been found to in-
crease serum cholesterol and
triglyceride concentrations, and
effect of olanzapine in increasing
cholesterol concentration has
been found to be associated with
weight gain (4, 5).
Weight gain, metabolic
changes and treatment
regimes
Management of a schizophrenic
patient includes a somatic exami-
nation at the initial stage of the
treatment and regularly thereafter
(at about 6–12 month intervals),
the aim of which is to identify
any other somatic diseases and
any adverse reactions in the
schizophrenic patient, which are
associated with the treatment
(Table), (6). The intervals shown
in the table, at which the labora-
tory tests are repeated, are given
as a guideline, and depending on
a clinical assessment, there may
even be a need for more frequent
tests. Monitoring of weight, or
the weight index, monthly or at
appointments, is also recom-
mended, including ECG monitor-
ing (before the introduction of
drug treatment and once the
dosage is stabilised) especially in
patients on high doses of antipsy-
chotics. According to internation-
al studies, every other schizo-
phrenic patient has a problem
with intoxicants, but the propor-
tion of intoxicant abusers was
smaller among Finnish patients.
To identify any problems with in-
toxicants it is recommended that
in addition to the patient, the pa-
tient’s nearest relatives be inter-
viewed and that laboratory as-
says be used to supplement the
somatic examination.
Correct choice of antipsychot-
ic, avoidance of polypharmacy,
nutritional guidelines, regular
monitoring of weight, and partic-
ipation in a diet programme as
necessary, may reduce the ad-
verse reactions caused by weight
gain and changes in metabolism.
Nutritional guidelines are aimed
at reducing the amount of harm-
ful fat contained in the diet, and
exercise is aimed at reducing the
calorie consumption, although
only modest results have been
achieved with the latter. Weight
monitoring is of particular im-
portance during the first weeks
and months of treatment. Since
weight gain and metabolic
changes may be associated with
the antipsychotic dose given, use
of the smallest effective dose in
TABU 4. 200846
In English
Follow-up of symptoms in patients using antipsychotics
Medication
initiation
4 weeks after 
initiation 
8 weeks after 
initiation 
12 weeks after 
initiation 
Every third
month
Yearly Every fifth
years
Family background (diabetes, lipid 
metabolism dysunction, sudden death)
x x
Weight (weight index) x x x x x
Waistline x x
Blood pressure x x x
Fasting glucose x x x
Lipids (total cholesterol, HDL- and 
LDL-cholesterol, triglycerides)
x x x
the treatment of the psychosis is
also justified from this point of
view (1). Replacing the antipsy-
chotic with another one may also
be beneficial, because diabetes
may disappear in the changeover
to another drug. Recommenda-
tions for a replacement do, how-
ever, require further comparisons
between different molecules.
According to present knowl-
edge, the importance of drug
therapy aimed at weight control
is minor, because many of the
drugs used in weight control have
an effect on the dopamine and
serotonin receptors in the same
way that antipsychotics do. Con-
sequently, for example, the use of
sibutramine, originally developed
as a antidepressant with an inhib-
itive effect both on noradrenalin
and serotonin re-uptake, has been
considered as being contraindi-
cated in patients suffering from a
psychosis, because of the risk of
adverse effects linked to its
monoamine re-uptake inhibition
such as exacerbation of psychosis
and serotonin syndrome. In-
creased prolactin secretion caused
by dopamine receptor blockade
can increase androgen produc-
tion, and the change in the oe-
strogen/androgen ratio may in-
crease appetite and fatty accumu-
lation. In cases followed up over
a longer period, with an opposite
effect, the dopamine agonist
amantadine has been found to
stop the weight gain associated
with the use of olanzapine, for
example, and to decrease pa-
tients’ weight. The use of aman-
tadine is nevertheless associated
with the risk of exacerbation of
psychotic symptoms. Orlistat,
with its effect on fat absorption,
is a drug with a proven efficacy
in weight reduction, but there is
insufficient evidence available on
its use in cases of weight gain as-
sociated with antipsychotic use.
In addition to a diet, treatment of
fat metabolism disorders in psy-
chotic patients with, for example,
statins, is a possibility, but further
studies are still needed in order to
provide proper treatment recom-
mendations. Adverse cardiovascu-
lar events caused by a fat metab-
olism disorder may be reduced by
using small doses of acetylsali-
cylic acid. 
The clinical significance of
metabolic disorders caused by
antipsychotics
Patients have a very negative atti-
tude towards antipsychotic thera-
py if, despite the medication, sig-
nificant positive hallucination
symptoms occur and the therapy
causes tiredness. Consequently,
particularly in the treatment of
schizophrenia and the other most
severe psychoses, more effective
drug therapies with improved tol-
erability are needed. The above-
mentioned adverse reactions, re-
flected in weight gain and adverse
metabolic reactions do not elimi-
nate the positive effects of an-
tipsychotic therapy. In addition to
more effective alleviation of psy-
chotic symptoms, benefits of the
second generation products also
include decreased adverse neuro-
logical symptoms and a beneficial
effect on the patient’s cognition,
symptoms of depression and sui-
cide mortality. The choice of drug
should still be based on assess-
ment of the patient’s entire situa-
tion and not only of isolated ad-
verse reactions. New understand-
ing is nevertheless needed about
the importance of the above-men-
tioned advantages and disadvan-
tages in long-term treatment.
Efforts should be made to re-
duce the adverse reactions caused
by medication; for example, by
appropriate monitoring of the ef-
fects on weight and metabolism
in patients on regular antipsy-
chotic therapy, as part of the pa-
tient’s total clinical monitoring. Si-
multaneous efforts can be made to
influence any other health risk fac-
tors (smoking, hypertension, dia-
betes) as part of the treatment
arrangements. In order for the out-
come of treatment and any associ-
ated adverse reactions to be moni-
tored, patient records should con-
tain adequate information to give
detailed account of how the treat-
ment was carried out.
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Surveillance of tissue establishments in Finland
2007 was a busy year for tissue
establishments and the National
Agency for Medicines (NAM),
which is responsible for tissue
regulation, because three EU Di-
rectives regulating the services of
the establishments were adopted
nationally within just a short
time frame. According to the
new regulations, tissue establish-
ments need to be licensed. The
quality and safety of human tis-
sues and cells are safeguarded
through the licensing of tissue
services, the appointment of the
responsible individuals, trained
and experienced personnel, ap-
propriate premises, equipment
and materials, and the documen-
tation relating to the services.
An amendment to the Human
Tissue Act (101/2001) regarding
the medical use of human organs
and tissues entered into force on
1.6.2007. The reformed Act im-
plemented the European Parlia-
ment and Council Tissue Direc-
tive 2004/23/EC at national lev-
el. According to the reformed
Tissue Act, all tissue establish-
ments operating in Finland need-
ed to apply to NAM for a licence
for their operation by 1.9.2007
at the latest. Those tissue estab-
lishments which submitted their
application for a licence by the
due date then had the right to
continue their operations until
the licensing issue was resolved.
The Decree of the Ministry of
Social Affairs and Health regard-
ing medical use of human tissues
and cells (1302/2007) and
NAM’s Administrative Regula-
tion regarding technical require-
ments for the operation of tissue
establishments (3/2007) came in-
to force on 28.12.2007. The De-
cree and the Administrative Reg-
ulation were followed by the na-
tional implementation of the
Commission Directives
2006/17/EC and 2006/86/EC.
The regulation of tissue estab-
lishments represented a new area
of responsibility for NAM, con-
sisting, for example, in establish-
ing regulatory and licensing pro-
cedures and providing guidelines
and advice to the establishments.
As the regulations focussed on
the quality and safety of human
tissues and cells, in its new area
of responsibility NAM was able
to make full use of its experience
in the quality and safety regula-
tion of drugs and blood products
and the regulation of medical de-
vices.
When the amendment to the
Tissue Act came into force, NAM
organised a meeting for the oper-
ators of tissue establishments,
where the new tissue safety legis-
lation and associated require-
ments were discussed. A total of
43 representatives from various
tissue establishments around Fin-
land attended the meeting. Dur-
ing a lively discussion it was ar-
gued that adopting the quality
and safety requirements in such a
way as to suit various, very dif-
ferent types of tissues and cells
could pose a particular challenge.
Further concern was expressed as
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to whether the information re-
garding the applicable require-
ments would reach all of the op-
erators. In addition to the impor-
tance of NAM communicating
with the operators on the respon-
sibility of the operators them-
selves to follow and comply with
the legislation.
Information reagrding regula-
tion of tissue establishments was
added to NAM’s website. To help
licence applicants and to improve
the licensing process, a licence
application form was included on
the website. The form also in-
cludes details about the reports
required for the licence applica-
tion as set out in the Decree
(773/2007) that came into force
on 20.7.2007. There are links to
current rules and regulations gov-
erning tissue establishments. Dur-
ing the summer and autumn of
2007, regulatory officers respon-
sible for the regulation of tissue
establishments responded to nu-
merous requests for information
relating to licences and the appli-
cation process.
At the turn of the year
2007/2008, when all three direc-
tives were nationally implement-
ed, NAM provided all licence ap-
plicants with an information pack
about the national legal provi-
sions. Operators were also re-
minded of the national reviews
with regard to emergency situa-
tions affecting tissue and cell im-
ports, and communication proce-
dures regarding tissue vigilance.
Applications
Over 600 licence applications
from about 70 establishments,
were submitted to NAM by the
due date. The majority of the ap-
plications were from fertility
treatment units using gametes,
bone banks, and units conducting
stem cell therapy (blood and bone
marrow stem cells). Applications
were also submitted for licences
for the handling and storage of
eye cornea and sclera, amnia, car-
diac valves and skin (Fig. 1).
Preliminary inspections
NAM inspects all of the opera-
tors and establishments applying
for an accredited tissue establish-
ment licence. By June 2008, regu-
latory officers responsible for tis-
sue establishments will have in-
spected a total of about 58 units,
i.e. 80% of all applicants. The
purpose of the preliminary in-
spections was to make a practical
assessment of the prerequisites
for applicants to carry on their
business as tissue establishments.
Particular efforts were made to
find staff involved in the practical
work of these establishments who
could also participate in NAM’s
inspection duties. In addition to
their regulatory component, in-
spections have also typically pro-
vided opportunities for delivering
guidelines and advice.
Inspections start with an in-
troductory discussion, during
which the inspectors elaborate on
tissue regulation and associated
legal stipulations, while the oper-
ators describe the general features
of their own business. This is fol-
lowed by a review of the estab-
lishment’s compliance with all
important quality and safety re-
quirements.
The inspection ends with a fi-
nal discussion, during which the
observations made by the inspec-
tors and any defects noted are re-
viewed together with the opera-
tor, following which the subse-
quent stages of the licensing
process are discussed. An inspec-
tion protocol is kept, in which
observations made during the in-
spection and any defects noted
are duly recorded. The operator
is supplied with a copy of the
protocol after the inspection. At
the same time, NAM will request
a report and schedule of the re-
medial actions that are to be tak-
en to rectify the defects. The li-
cence will be prepared at NAM
based on the application docu-
ments, preliminary inspection,
and any additional reports sub-
mitted.
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In the assessment of each
tissue establishments’ and its
operations’ compliance with
regulations, particular attention
is given to the following issues
• Designating a responsible 
person and ascertaining that
he/she is appropriately 
qualified
• Introduction to duties, formal
qualification and further 
training of staff
• Quality assurance system
• Auditing of the business and
its quality assurance system
• Processing and assessment of
any defects
• Tissue safety; processing of
and reporting on any serious
adverse reactions associated
with tissue and cell quality
and safety, and any serious
adverse events
• Tissue and cell procurement
procedures; donor recruit-
ment, consent, assessment and
infection testing
• Handling, preservation and
storage of tissues and cells
• Release into use and distribu-
tion of tissues and cells
• Premises; in particular the
premises for handling and
storing tissues and cells 
including monitoring of their
condition
• Ensuring the availability and
faultless operation of all 
essential equipment
• Essential materials, with
batch monitoring
• Full traceability of data
During the inspections of the
58 establishments, a total of 357
defects were recorded, 23 (6.4%)
of which were assessed as critical
or serious. The critical defects
were associated with inaccuracies
in the mandatory infection test-
ing of tissue or cell donors. Seri-
ous defects related typically to
establishments’ premises which
did not, in all their parts, fulfil
the requirements applicable to
tissue handling facilities.
The majority of the defects
identified related to quality sys-
tems and inadequate documenta-
tion of operations. The range of
defects found can be seen in Fig.
2.
Licences
So far, NAM has issued 21 li-
cences for tissue establishments,
and one emergency licence for
import. Units inspected in the
spring have actively submitted
additional reports which were
necessary for completion of the
licence, and new licences are cur-
rently being prepared. A list of
accredited tissue establishments
is published by NAM. The list is
available on the NAM website.
Licensed tissue establishments are
inspected at two-yearly intervals,
in accordance with regulations.
Concerning fertility treatment
services, tissue establishments
which handle gemetes also need a
licence from the National Board
of Medicolegal Affairs, in accor-
dance with the legislation gov-
erning fertility treatment. The li-
censing procedures of this Board
and NAM have in part proceed-
ed in parallel, with active collab-
oration between the authorities.
Tissue vigilance
Any situations that could jeopar-
dise the quality and safety of tis-
sues and cells should be assessed
by the individual tissue establish-
ment, with the establishment it-
self planning and taking remedial
action. Serious adverse reactions
and serious adverse events should
be reported to NAM. In 2007,
ten reports relating to serious
hazardous situations were issued,
concerning defects identified in
the storage and distribution pro-
cedures for tissues and cells, and
microbial contamination of
transplants.
Projects in the immediate
future
The European coding system that
is currently under development
will pose a challenge both to tis-
sue establishments and to the reg-
ulatory authorities. Its aim is to
give each donated product an in-
dividual European code, by
which the donor and the trans-
plant can be reliably identified
and traced. 
The Commission has been ac-
tive in initiating projects to aid
the setting up and development
of quality systems, including har-
monising the way in which they
are monitored.
Tissue establishments operated
in Finland before the implemen-
tation of the directives, and con-
tinue to do so today. It is hoped
that the new common require-
ments will help to further clarify
and harmonise practice at tissue
establishments, and increase con-
fidence both in Finland and
abroad in the quality and safety
of donated tissues and cells.
TABU 4. 200850
In English
0
5
10
15
20
25
30
35
40
45
Tra
ini
ng
do
cu
me
nt
ati
on
Pre
mi
se
s a
nd
en
vir
on
me
nt
al
mo
nit
ori
ng
Tis
su
ev
igi
lan
ce
Au
dit
sys
tem
Re
lea
sin
g p
roc
ed
ure
La
bo
rat
ory
tes
ts
for
do
no
rs
Eq
uip
me
nt
an
d m
on
ito
rin
g
Tra
ce
ab
ilit
y
De
scr
ipt
ion
of
the
reg
ist
er
Job
de
scr
ipt
ion
s
De
via
tio
n d
oc
um
en
tat
ion
Re
sp
on
sib
le
pe
rso
ns
Pro
cu
rem
en
t p
roc
ed
ure
s
Qu
ali
ty
sys
tem
Ot
he
rs
Am
ou
nt
of
de
fe
ct
s
Fig. 2.
The amount of counterfeit medi-
cines increase rapidly throughout
the world.  As well international
organizations (1, 2) as national
authorities (3, 4) work actively to
counteract traffic of counterfeit
medicines. Since 2006 the
seizures of counterfeit medicines
done buy the customs at the EU's
external border have increased by
51% (5). The number of medi-
cines and diverse counterfeit
medicines seized by the Finnish
Customs has also increased year
after year (6). In Finland counter-
feit medicines have, nevertheless,
not reached the legitimate supply
chain.
Although it is in most cases il-
legal, Finns frequently order po-
tency promoters and doping sub-
stances through international
websites. Samples confiscated at
the Customs Post Office or seized
from travelers at the Finnish bor-
ders are analyzed by the Finnish
Customs Laboratory. For an
eventual crime investigation, it is
sufficient to identify any active
pharmaceutical ingredient (API)
in the sample; thus the focus is
on qualitative analyses. Counter-
feit medicines containing wrong
APIs constitute, however, a seri-
ous safety concern and are there-
fore of special interest for the au-
thorities supervising medicines.
The laboratory of the National
Agency for Medicines (NAM) has
examined samples confiscated by
the Finnish Customs by using
qualitative and quantitative meth-
ods. This article presents five ex-
amples of counterfeit medicines
that contain wrong APIs (table).
Kamagra tablets containing
chloroquine 
Many of previously studied Kam-
agra-samples have contained the
right API (sildenafil). Hence the
Kamagra tablets in Fig. 1, con-
taining the antimalarial agent
chloroquine, are exceptional. A
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Sample Source Expected content Content
Kamagra 100 tablets, 
7–081
Thailand (traveler) Sildenafil 100 mg Chloroquine2 0,8 mg
Kamagra 100 tablets, 
8–081
Thailand (traveler) Sildenafil 100 mg Chloroquine2 2,4 mg
Kamagra tablets, 
9–081, tablett 1
Thailand (traveler) Sildenafil 100 mg Sildenafil 15,3 mg
Chloroquine 2 1,1 mg
Kamagra tablets 
9–081, tablett 2
Thailand (traveler) Sildenafil 100 mg Sildenafil 10,8 mg
Chloroquine
Sulfamethoxazole
Cialis “new tadalafil”   
tablets
China (internet) Tadalafil 50 mg Sildenafil 129 mg
Tamoxifen 10 tablets Slovakia (internet) Tamoxifen 10 mg Sildenafil 2,3 mg
1 Internal laboratory sample number
2 Diphosphate salt
Fig. 1. Kamagra tablets.
warning about Kamagra tablets
has been published on the web-
site of NAM (7). 
The amount of chloroquine in
all investigated Kamagra samples
was very low. In samples 7–08
and 8–08 no sildenafil was de-
tected, whereas sample 9–08 con-
tained a small amount of it. In
one of the tablets another extra
peak, representing an unknown,
was detected in the chromatog-
ram (Fig. 2. See figures 2–5 on
pages 14–15). The tablet was re-
analyzed with a liquid chromato-
graph coupled to a diode-array
detector and a mass spectrometer.
On the basis of comparison of re-
tention times, UV- and MS-spec-
tra of the unknown substance in
the sample and a reference stan-
dard, the extra peak was identi-
fied as sulfamethoxazole (Fig. 3).
Cialis from China with Finnish
text on the label
Erectile dysfunction medications
are one of the most counterfeited
medicinal products. The sample
analyzed by the Customs Labora-
tory and the laboratory of NAM
was a fraudulent Cialis tablet
containing a considerable amount
of sildenafil instead of tadalafil
(Figs 4 and 5). Although the
tablets closely resembled the orig-
inal ones, the packing was not an
imitation (Fig. 6a–b). The label
was in English, but surprisingly,
the name of the API was also giv-
en in Finnish (tadalafiili). The
product was probably targeted
specially for the Finnish market.
Tamoxifen tablets containing
sildenafil only
In this example tablets called
"Tamoxifen 10" (Fig. 7) did not
contain the antiestrogen tamox-
ifen, used for treatment of breast
cancer, but a low content (2.3
mg) of sildenafil (Fig. 8). 
Conclusions
Medicines containing incorrect
APIs can be specially detrimental
to health, because  
• they lack the intended pharma-
cological effect   
• the wrong active pharmaceuti-
cal ingredients may cause surp-
rising effects which can be diffi-
cult to link to the medicine
There seems not to be any ra-
tionale behind producing and
marketing counterfeit medicines
containing wrong APIs, especially
not in producing medicines with
very low and sub-therapeutic con-
tents of such substances. For ex-
ample the Kamagra tablets inves-
tigated contained only 1–2 mg of
chloroquine (common content is
250 mg/tablet) and the Tamox-
ifen tablets contained only 2 mg
of sildenafil (common content is
25–100 mg/tablet).
The surprising findings de-
scribed above could perhaps re-
sult from
• contaminated production lines
• use of leftovers from production
of other medicines/counterfeit
medicines
• intentional or unintentional er-
rors in the production of the
counterfeit medicines
The examples in this article clear-
ly demonstrate the dangers and
problems associated with coun-
terfeit medicines and illegal trade
in medicines. To minimize the il-
legal trade and the resulting safe-
ty concerns it is important to con-
tinue and further develop the col-
laboration between authorities in
the fight against counterfeit medi-
cines.
See references on page 15.
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